Evaluation of Strategies to Enhance Community-Based Naloxone Distribution Supported by an Opioid Settlement.


Journal

JAMA network open
ISSN: 2574-3805
Titre abrégé: JAMA Netw Open
Pays: United States
ID NLM: 101729235

Informations de publication

Date de publication:
01 May 2024
Historique:
medline: 30 5 2024
pubmed: 30 5 2024
entrez: 30 5 2024
Statut: epublish

Résumé

Many US states are substantially increasing community-based naloxone distribution, supported in part through settlements from opioid manufacturers and distributors. To evaluate the potential impact of increased naloxone availability on opioid overdose deaths (OODs) and explore strategies to enhance this impact by integrating interventions to address solitary drug use. This decision analytical modeling study used PROFOUND (Prevention and Rescue of Fentanyl and Other Opioid Overdoses Using Optimized Naloxone Distribution Strategies), a previously published simulation model, to forecast annual OODs between January 2023 and December 2025. The simulated study population included individuals from Rhode Island who misused opioids and stimulants and were at risk for opioid overdose. The study modeled expanded naloxone distribution supported by the state's opioid settlement (50 000 naloxone nasal spray kits each year). Two approaches to expanding naloxone distribution were evaluated: one based on historical spatial patterns of naloxone distribution (supply-based approach) and one based on the spatial distribution of individuals at risk (demand-based approach). In addition, hypothetical interventions to enhance the likelihood of witnessed overdoses in private or semiprivate settings were considered. Annual number of OODs and ratio of fatal to nonfatal opioid overdoses. Modeling results indicated that distributing more naloxone supported by the state's opioid settlement could reduce OODs by 6.3% (95% simulation interval [SI], 0.3%-13.7%) and 8.8% (95% SI, 1.8%-17.5%) in 2025 with the supply-based and demand-based approaches, respectively. However, increasing witnessed overdoses by 20% to 60% demonstrated greater potential for reducing OODs, ranging from 8.5% (95% SI, 0.0%-20.3%) to 24.1% (95% SI, 8.6%-39.3%). Notably, synergistic associations were observed when combining both interventions: increased naloxone distribution with the 2 approaches and a 60% increase in witnessed overdoses could reduce OODs in 2025 by 33.5% (95% SI, 17.1%-50.4%) and 37.4% (95% SI, 19.6%-56.3%), respectively. These findings suggest that interventions to address solitary drug use are needed to maximize the impact of continued efforts to increase community-based naloxone distribution, which may be particularly important for jurisdictions that have strong community-based naloxone distribution programs.

Identifiants

pubmed: 38814644
pii: 2819204
doi: 10.1001/jamanetworkopen.2024.13861
doi:

Substances chimiques

Naloxone 36B82AMQ7N
Narcotic Antagonists 0
Analgesics, Opioid 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e2413861

Auteurs

Xiao Zang (X)

Division of Health Policy and Management, School of Public Health, University of Minnesota, Minneapolis.

Alexandra Skinner (A)

Department of Epidemiology, School of Public Health, Brown University, Providence, Rhode Island.

Maxwell S Krieger (MS)

Department of Epidemiology, School of Public Health, Brown University, Providence, Rhode Island.

Czarina N Behrends (CN)

Department of Population Health Sciences, Weill Cornell Medical College, New York City, New York.

Ju N Park (JN)

Department of Medicine, Brown University, Providence, Rhode Island.

Traci C Green (TC)

The Heller School for Social Policy and Management, Brandeis University, Waltham, Massachusetts.

Alexander Y Walley (AY)

Department of Medicine, Section of General Internal Medicine, Boston Medical Center and Boston University School of Medicine, Boston, Massachusetts.

Jake R Morgan (JR)

Department of Health Law, Policy & Management, Boston University School of Public Health, Boston, Massachusetts.

Benjamin P Linas (BP)

Section of Infectious Diseases, Boston Medical Center, Boston, Massachusetts.
Department of Medicine, Boston University School of Medicine, Boston, Massachusetts.

Jesse L Yedinak (JL)

Department of Epidemiology, School of Public Health, Brown University, Providence, Rhode Island.

Bruce R Schackman (BR)

Department of Population Health Sciences, Weill Cornell Medical College, New York City, New York.

Brandon D L Marshall (BDL)

Department of Epidemiology, School of Public Health, Brown University, Providence, Rhode Island.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH